NCI
Micronoma, NYU Partner to Develop Microbial Biomarkers of Lung Cancer
Micronoma aims to commercialize the biomarkers as a test based on its OncobiotaLUNG microbiome-based liquid biopsy platform.
NCI Launches Trial of ImmunityBio Vaccine Combo to Prevent Cancer Among Lynch Syndrome Patients
Lynch syndrome patients will receive Tri-Ad5, a three-vaccine combination, along with an immune enhancer to train their immune system to attack precancerous cells.
Eureka Therapeutics Licenses Antibody From NCI to Develop Mesothelin-Targeting Cell Therapy
The firm will combine the antibody with its Artemis cell therapy platform to develop and commercialize a treatment for patients with mesothelin-expressing solid tumors.
Aprea Therapeutics Receives $2M in NCI Funding to Explore DNA Damage Inhibitors in Ovarian Cancer
The funding will go toward preclinical studies evaluating Aprea's ATR inhibitor and WEE1 inhibitor combination in ovarian cancer.
Gritstone Bio, NCI Collaborate on Cancer Vaccine, Cell Therapy Combo Study in KRAS-Mutant Tumors
The partners will study the activity of Gritstone's KRAS-directed vaccine candidate with an autologous T-cell therapy developed at the NCI.